Charles Schwab Investment Management Inc Nuvectis Pharma, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Nuvectis Pharma, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 37,982 shares of NVCT stock, worth $228,651. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,982
Previous 37,982
-0.0%
Holding current value
$228,651
Previous $283,000
19.43%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding NVCT
# of Institutions
54Shares Held
3.62MCall Options Held
97.7KPut Options Held
0-
Vanguard Group Inc Valley Forge, PA699KShares$4.21 Million0.0% of portfolio
-
Ronit Capital LLP563KShares$3.39 Million5.37% of portfolio
-
Iridian Asset Management LLC406KShares$2.44 Million1.02% of portfolio
-
Baldwin Brothers LLC350KShares$2.11 Million0.15% of portfolio
-
Geode Capital Management, LLC Boston, MA326KShares$1.96 Million0.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $88.1M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...